Dyadic International (DYAI)

Overall impact
B (66)

Commentary

Dyadic International is a strong overall performer. With a 'B' rating of 65.9 for overall impact (75th percentile compared to all companies), Dyadic International ranks 20th out of 151 industry peers, behind Northern Technologies International, Pure Bioscience, Chr Hansen and 16 others, and ahead of Amyris, Aemetis, Gulf Resources and 128 others. On top material causes for Dyadic International's industry (Chemicals), Dyadic International performs well in Reduced Waste (95.3 score), Fair Labor Practices (84.8), Humane Treatment of Animals (96.2) and 1 other cause where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (12.7 score).
Impact
Cause DYAI
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1979
Employees
5
Sector
Materials
Industry
Chemicals
Sub-industry
Specialty Chemicals
SASB industry
Chemicals
Headquarters
Fl, United States
Share classes
DYAI
Description
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Material causes
Ethos considers the following causes material for Dyadic International, based on its industry sub-industry Specialty Chemicals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.